Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy

Wendy Allen, Philip Dunne, Simon McDade, Enya Scanlon, Maurice Loughrey, Helen Coleman, Christopher McCann, Kristy McLaughlin, Zsuzsanna Nemeth, Najeeb Ashraf Syed, Puthen Veettil Jithesh, Ken Arthur, Richard Wilson, Victoria Coyle, Darragh McArt, Patrick Johnston, Graeme I Murray, Leslie M Samuel, Paolo Nuciforo, Jose JimenezGuillem Argiles,, Rodrigo Dienstmann, Lucia Picariello, Stefania Nobili, Enrico Mini, Kieran Sheahan, Elizabeth Ryan, Josef Tabernero, Luca Messerini, Sandra Van Schaeybroeck, Mark Lawler, Daniel Longley

Research output: Contribution to journalArticle

256 Downloads (Pure)


Purpose: Transcriptomic profiling of colorectal cancer (CRC) has led to identification of four consensus molecular subtypes (CMS1-4), which have prognostic value in stage II/III disease. More recently, the Colorectal Cancer Intrinsic Subtypes (CRIS) classification system has helped to define the biology specific to the epithelial component of colorectal tumors. However, the clinical value of these classifications in predicting response to standard-of-care adjuvant chemotherapy remains unknown.

Patients and Methods: Using samples from 4 European sites, we assembled a novel stage II/III CRC patient cohort and performed transcriptomic profiling on 156 samples, targeted sequencing and generated a tissue microarray to enable integrated "multi-omics" analyses. We also accessed data from 2 published stage II/III CRC patient cohorts: GSE39582 and GSE14333 (479 and 185 samples respectively).

Results: The epithelial-rich CMS2 subtype of CRC benefitted significantly from adjuvant chemotherapy treatment in both stage II and III disease (p=0.02 and p<0.0001 respectively), while the CMS3 subtype significantly benefitted in stage III only (p=0.00073). Following CRIS sub-stratification of CMS2, we observed that only the CRIS-C subtype significantly benefitted from adjuvant chemotherapy in stage II and III disease (p=0.0081 and p<0.0001 respectively), while CRIS-D significantly benefitted in stage III only (p=0.0034). We also observed that CRIS-C patients with low levels of CD8+ tumor-infiltrating lymphocytes were most at risk of relapse in both stage II and III disease (p=0.0031).

Conclusion: Patient stratification using a combination of transcriptional subtyping and CD8 immunohistochemistry analyses is capable of identifying poor prognostic stage II/III patients who benefit from adjuvant standard-of-care chemotherapy. These findings are particularly relevant for stage II disease, where the overall benefit of adjuvant chemotherapy is marginal.

Original languageEnglish
Pages (from-to)1-15
Journal JCO Precision Oncology
Publication statusPublished - 13 Jun 2018


Cite this